Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity (Tables)

v3.22.2
Stockholders' Equity (Tables)
6 Months Ended
Jun. 30, 2022
Stockholders' Equity  
Summary of restricted stock award activity

Weighted Average

Number of

Grant Date Fair

    

Shares

    

Value  

Non-vested at December 31, 2021

4,512,701

$

3.35

Granted

1,529,214

2.04

Forfeited

(84,000)

2.75

Vested

(2,074,710)

3.68

Non-vested at June 30, 2022

3,883,205

$

2.67

Summary of stock option award activity

The following table summarizes stock option award activity for the six months ended June 30, 2022:

Weighted Average 

Remaining

Weighted Average 

 Contractual Life

    

Stock Options 

    

Exercise Price

    

(in years)

Outstanding as of December 31, 2021

270,000

$

3.14

7.44

Granted

40,000

1.42

9.92

Outstanding as of June 30, 2022

310,000

$

2.91

7.32

Vested and exercisable as of June 30, 2022

155,000

$

2.31

7.39

Summary of stock options assumptions used

For the Six Months Ended June 30, 

 

    

2022

    

2021

 

Risk-free interest rate

 

1.30

%

1.04% - 1.50

%

Expected dividend yield

 

Expected term in years

 

10.0

10.0

Expected volatility

 

100.65

%

100.65% - 102.71

%

Summary of warrant activities

A summary of warrant activities for the six months ended June 30, 2022 is presented below:

Weighted Average 

Remaining

Weighted Average 

Contractual Life

    

Warrants 

    

Exercise Price 

    

(in years)

Outstanding as of December 31, 2021

12,493

$

0.00

3.83

Exercised

Outstanding as of June 30, 2022

12,493

$

0.00

3.33

Summary of stock-based compensation expense

The following table summarizes stock-based compensation expense for the three and six months ended June 30, 2022 and 2021 ($ in thousands):

For the three months ended June 30, 

For the six months ended June 30, 

    

2022

    

2021

    

2022

    

2021

Research and development

$

229

$

158

$

476

$

319

General and administrative

 

500

 

608

 

1,028

 

1,221

Total stock-based compensation expense

$

729

$

766

$

1,504

$

1,540